Melissa Epperly Named CFO of Tenpoint Therapeutics
Slice of Healthcare Team
06/04/2025
Key highlights
- Melissa Epperly appointed Chief Financial Officer at Tenpoint
- Brings 20+ years of financial leadership in biopharma
- Will guide financial strategy for BRIMOCHOL™ PF U.S. launch
- Previously CFO at Zentalis Pharmaceuticals, raising $1.25B+
- Holds roles on audit boards at Roivant Sciences and Nautilus Biotechnology
Notable Quotes
“ Melissa brings the vision, energy, and financial firepower we need as we prepare for the launch of BRIMOCHOL™ PF into global markets. ”
Henric Bjarke, Chief Executive Officer at Tenpoint Therapeutics
“ It’s an honor to join Tenpoint at such a defining moment. ”
Melissa Epperly, Chief Financial Officer at Tenpoint Therapeutics
Why This Matters
Melissa Epperly's appointment as CFO marks a pivotal move for Tenpoint Therapeutics as it transitions from clinical development to potential commercialization. Her extensive capital markets experience and biopharma acumen position the company for financial strength and operational readiness as it prepares to bring BRIMOCHOL™ PF—a treatment targeting presbyopia affecting two billion people globally—to market. This leadership addition underscores Tenpoint’s commitment to scaling its vision-restoring innovations.
